Latest guidance  

COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
COVID-19 rapid guideline: managing COVID-19
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
RenalSense Clarity RMS for acute kidney injury

Latest guidance in consultation  

Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
Weight Management
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]

Explore NICE

  1. News|
  2. About|
  3. Events|
  4. Get involved

Latest news  

  1. NICE recommends range of effective treatments for people with chronic primary pain and calls on healthcare professionals to recognise and treat a person’s pain as valid and unique to them
  2. NICE publishes single guideline for managing COVID-19
  3. Triple therapy recommended by NICE for patients with multiple myeloma
  4. Unpaid carers should be offered advice and support, says NICE

Tweets

by @NICEcomms